Abstracts tagged "Outcome measures"

Abstract Number: 2335 • 2014 ACR/ARHP Annual Meeting
Reliability and Validity of the Arthritis Helplessness Index in Systemic Sclerosis
Shadi Gholizadeh¹, Sarah D. Mills², Rina S. Fox², Philip J. Clements³, Suzanne Kafaja⁴, Vanessa L. Malcarne⁵, Daniel E. Furst⁶ and Dinesh Khanna⁷, ¹Psychology, SDSU/UCSD Joint Doctoral Program in Clinical Psychology, San Diego, CA, ²SDSU/UCSD Joint Doctoral Program in Clinical Psychology, San Diego, CA, ³University of California, Los Angeles, Department of Medicine, Los Angeles, CA, ⁴Medicine, University of California, Los Angeles, Department of Medicine, Los Angeles, CA, ⁵Psychology, SDSU/UCSD Joint Doctoral Program in Clinical Psychology; Department of Psychology, San Diego State University, San Diego, CA, ⁶Medicine/ Rheumatology, University of California, Los Angeles, Department of Medicine, Los Angeles, CA, ⁷University of Michigan Health System, Ann Arbor, MI
Background/Purpose: The unpredictable and uncontrollable course of rheumatic diseases has made them an interesting area of study in the learned helplessness and health outcomes literature.…
Abstract Number: 1987 • 2014 ACR/ARHP Annual Meeting
Simulation in Continuing Education: Improving Evidence-Based Decisions for Rheumatoid Arthritis Management
Nimish Mehta¹, Martin Warters² and Douglas Blevins², ¹Medscape, LLC, New York, NY, ²Therasim, Durham, NC
Background/Purpose In many patients with rheumatoid arthritis (RA), the disease is not adequately controlled, and only a minority of patients attain the goal of consistent…
Abstract Number: 1779 • 2014 ACR/ARHP Annual Meeting
Plasmapheresis Therapy in ANCA-Associated Vasculitides: A Single-Center Retrospective Analysis of Renal Outcome and Mortality
David Solar-Cafaggi¹, Yemil Atisha-Fregoso¹ and Andrea Hinojosa-Azaola², ¹Internal Medicine, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico, ²Immunology and Rheumatology, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico
Background/Purpose: ANCA-associated vasculitides (AAV) are rare, potentially fatal diseases with multiorgan involvement. Evidence for the use of plasmapheresis (PLEX) in patients with severe forms of…
Abstract Number: 2238 • 2013 ACR/ARHP Annual Meeting
Comparison Of The Long-Term Outcome For Rheumatoid Arthritis Patients With persistent Moderate Disease Activity Or Disease Remission During The First Year After Diagnosis: Data From The Espoir Cohort
Bernard Combe¹, Isabelle Logeart², M. Belkacemi³, S Dadoun⁴, Jean-Pierre Daurès⁵ and Maxime Dougados⁶, ¹Rheumatology, Lapeyronie Hospital, Montpellier I university, Montpellier, France, ²Pfizer, Paris, France, ³CHRU Montpellier, Montpellier, France, ⁴Paris-Pitié Salpêtrière University Hospital, Paris, France, ⁵Service BESPIM, CHU, Nimes, France, ⁶Rheumatology B Department, Paris-Descartes University, Cochin Hospital, Paris, France
Background/Purpose: The Treat to Target and EULAR recommendations highlighted the need for achieving and maintaining remission in patients with early RA. We investigated if early…
Abstract Number: 763 • 2013 ACR/ARHP Annual Meeting
The Risk Of Myocardial Infarction In Systemic Sclerosis: A Population-Based Cohort Study
Iman Hemmati¹, Hyon K. Choi^2,3, Kamran Shojania^3,4, Eric C. Sayre³ and J. Antonio Avina-Zubieta^3,5, ¹Deparment of Medicine and Rheumatology, University of British Columbia, Vancouver, BC, Canada, ²Section of Rheumatology and the Clinical Epidemiology Unit, Boston University School of Medicine, Boston, MA, ³Arthritis Research Centre of Canada, Richmond, BC, Canada, ⁴Rheumatology, University of British Columbia, Vancouver, BC, Canada, ⁵Rheumatology, Arthritis Research Centre of Canada, Richmond, BC, Canada
Background/Purpose: An increased risk of premature atherosclerosis has been well described in patients with rheumatoid arthritis and systemic lupus erythematosus. However, there is limited data…
Abstract Number: 2245 • 2013 ACR/ARHP Annual Meeting
Predictive Validity Of Low Disease Activity Using Patient Reported Measures On Long-Term Outcomes In Early Rheumatoid Arthritis- Results From Study Of New Onset Rheumatoid Arthritis and Ontario Best Practices Initiative
Pooneh Akhavan¹, Binu Jacob², Paul R. Fortin³, George A. Tomlinson⁴ and Claire Bombardier^5,6, ¹Medicine, Mount Sinai Hospital/University of Toronto, Toronto, ON, Canada, ²University Health Network, Toronto General Research Institute, Toronto, ON, Canada, ³University of Laval, Quebec, QC, Canada, ⁴Dept of Medicine/Rheumatology, Toronto General Hospital, Toronto, ON, Canada, ⁵Rheumatology, University of Toronto, Toronto, ON, Canada, ⁶Division of rheumatology and Department of Health Policy, Management, and Evaluation, University Health Network, Toronto, ON, Canada
Background/Purpose: Patient reported outcome measures (PROM) are used in routine practice for assessment of disease activity. They have been shown to correlate well with other…
Abstract Number: 482 • 2013 ACR/ARHP Annual Meeting
Methotrexate Use At Infliximab Initiation and Impact On Treatment Outcomes: An Analysis From A Canadian Registry
Denis Choquette¹, J. Carter Thorne², John T. Kelsall³, Michel Zummer⁴, Michael Starr⁵, Maqbool K. Sheriff⁶, William G. Bensen⁷, Andrew Chow⁸, Philip Baer⁹, Emmanouil Rampakakis¹⁰, John S. Sampalis¹⁰, Francois Nantel¹¹, Allen J. Lehman¹², Susan M. Otawa¹² and May Shawi¹³, ¹Rheumatology, Institut de rhumatologie de Montréal (IRM), Montréal, QC, Canada, ²Southlake Regional Health Centre, Newmarket, ON, Canada, ³Mary Pack Arthritis Centre, Vancouver, Vancouver, BC, Canada, ⁴Rheumatology, Ch Maisonneuve-Rosemont, Montreal, QC, Canada, ⁵Montreal General Hospital, Montreal, QC, Canada, ⁶Nanaimo Regional General Hospital, Nanaimo, BC, Canada, ⁷Department of Medicine, Division of Rheumatology, Clinical Professor, McMaster University, Hamilton, ON, Canada, ⁸University of Toronto, McMaster University, Credit Valley Rheumatology, Mississauga, ON, Canada, ⁹Private Practice, Scarborough, ON, Canada, ¹⁰JSS Medical Research, Montreal, QC, Canada, ¹¹Janssen Inc., Toronto, ON, Canada, ¹²Medical Affairs, Janssen Inc., Toronto, ON, Canada, ¹³Medical Affairs, Janssen Canada Inc, Toronto, ON, Canada
Background/Purpose: Clinical trials of anti-TNF therapies have shown that concurrent methotrexate (MTX) therapy enhances the efficacy of infliximab (IFX)1. Data on the benefits of combination…
Abstract Number: 2247 • 2013 ACR/ARHP Annual Meeting
Response To a Sleep Query On The Multi-Dimensional Health Assessment Questionnaire (MDHAQ) Is Related To Levels Of Disease Activity
Martin J. Bergman^1,2, Sapna Sangani³, Isabel Castrejón⁴ and Theodore Pincus⁴, ¹Medicine, Drexel University College of Medicine, Philadelphia, PA, ²Taylor Hospital, Ridley Park, PA, ³Medicine, Mercy Catholic Medical Center, Lansdowne, PA, ⁴Rheumatology, Rush University Medical Center, Chicago, IL
Background/Purpose: Patients with rheumatoid arthritis (RA) often report fatigue, but a possible impact of disease on sleep and/or on disease activity are poorly characterized. We…
Abstract Number: 453 • 2013 ACR/ARHP Annual Meeting
Impact Of Inadequate Adherence On Clinical Outcomes: Results From The Biologics In Rheumatoid Arthritis Genetics and Genomics Study Syndicate Cohort
James Bluett¹, Catharine Morgan¹, Layla Thurston², Darren Plant¹, Ann W. Morgan³, Anthony G. Wilson⁴, John Isaacs⁵, Kimme L. Hyrich¹, Lis Cordingley¹ and Anne Barton¹, ¹Arthritis Research UK Epidemiology Unit, The University of Manchester, Manchester, United Kingdom, ²Manchester Medical School, The University of Manchester, Manchester, United Kingdom, ³NIHR-Leeds Musculoskeletal Biomedical Research Unit and Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds, United Kingdom, ⁴Department of Infection and Immunity, University of Sheffield, Sheffield, United Kingdom, ⁵National Institute for Health Research, Newcastle Biomedical Research Centre, Newcastle Hospitals Foundation Trust and Newcastle University, Newcastle Upon Tyne, United Kingdom
Background/Purpose: Biologic therapy has revolutionised patient prognosis in rheumatoid arthritis (RA). In the UK, continuing biologic therapy requires a sustained response as determined by the…
Abstract Number: 2135 • 2013 ACR/ARHP Annual Meeting
Musculoskeletal Pain Explains Differences In Function At Time Of Surgery In Black TKR and THR Patients
Anthony Porter¹, Wenjun Li², Leslie R. Harrold¹, Milagros Rosal³, Philip Noble⁴, David Ayers², Patricia D. Franklin² and Jeroan Allison⁵, ¹University of Massachusetts Medical School, Worcester, MA, ²Orthopedics and Physical Rehabilitation, University of Massachusetts Medical School, Worcester, MA, ³Preventive and Behavioral Medicine, University of Massachusetts Medical School, Worcester, MA, ⁴Baylor College of Medicine, Houston, TX, ⁵Quantitative Health Sciences, University of Massachusetts Medical School, Worcester, MA
Background/Purpose: The existence of racial disparities in total knee (TKR) and total hip (THR) replacement outcomes is well established but not well understood. The burden…
Abstract Number: 429 • 2013 ACR/ARHP Annual Meeting
Sustained Clinical Efficacy After Multiple Courses of Rituximab in Rheumatoid Arthritis Patients With Inadequate Response to Tumour Necrosis Factor Inhibitors: 2-Year Data From the Repeat (Repeated Courses in Routine Clinical Practice) Study
Catalin Codreanu¹, Ioan Ancuta² and Ruxandra Ionescu³, ¹Rheumatology, “Dr. I. Stoia” Center for Rheumatic Diseases, Bucharest, Romania, ²“Dr. I. Cantacuzino” Hospital, Bucharest, Romania, ³Internal Medicine, Clinic Hospital Sf. Maria, Bucharest, Romania
Background/Purpose: In the last decade, biologic therapy changed dramatically treatment options for rheumatoid arthritis (RA). However, a significant number of patients failed to maintain the…
Abstract Number: 2136 • 2013 ACR/ARHP Annual Meeting
Does Functional Gain and Pain Relief After TKR and THR Differ By Patient Obese Status?
Wenjun Li¹, Leslie R. Harrold², Jeroan Allison³, Courtland Lewis⁴, Thomas Bowen⁵, Patricia D. Franklin¹ and David Ayers¹, ¹Orthopedics and Physical Rehabilitation, University of Massachusetts Medical School, Worcester, MA, ²University of Massachusetts Medical School, Worcester, MA, ³Quantitative Health Sciences, University of Massachusetts Medical School, Worcester, MA, ⁴Hartford Hospital, Hartford, CT, ⁵Geisinger, Danville, PA
Background/Purpose: Obesity is an important predictor of functional status and pain after total knee (TKR) and total hip (THR) replacement. However, variations in pre-post TKR…
Abstract Number: 314 • 2013 ACR/ARHP Annual Meeting
Impact Of Low Infliximab Dose Regimen On Treatment Response and Drug Survival In 462 Patients With Psoriatic Arthritis. Results From The Nationwide Registries Danbio and Icebio
Bente Glintborg^1,2, Bjorn Gudbjornsson^3,4, Niels Steen Krogh⁵, Emina Omerovic², Natalia Manilo⁶, Mette Holland-Fischer⁷, Hanne M. Lindegaard⁸, Anne Gitte Loft⁹, Henrik Nordin¹⁰, Laura Johnsen¹¹, Sussi Flejsborg Oeftiger¹², Annette Hansen¹³, Claus Rasmussen¹⁴, Gerdur Grondal¹⁵, Árni Jón Geirsson¹⁶ and Merete Lund Hetland^1,2,17, ¹The Danish Rheumatologic Database (DANBIO), Glostrup Hospital, Glostrup, Denmark, ²Copenhagen Center for Arthritis Research, Center for Rheumatology and Spine Diseases, Glostrup Hospital, Glostrup, Denmark, ³Department of Rheumatology, Center for Rheumatology Research (ICEBIO), Landspitali – The National University Hospital of Iceland, Reykjavik, Iceland, ⁴Faculty of Medicine, University of Iceland, Reykjavik, Iceland, ⁵ZiteLab ApS, Copenhagen, Denmark, ⁶Department of Rheumatology, Frederiksberg Hospital, Copenhagen, Denmark, ⁷Department of Rheumatology, Aalborg University Hospital, Aalborg, Denmark, ⁸Department of Rheumatology, Odense University Hospital, Odense, Denmark, ⁹Department of Rheumatology, Sygehus Lillebaelt, Vejle, Denmark, ¹⁰Department of Infectious Diseases and Rheumatology, Rigshospitalet, Copenhagen, Denmark, ¹¹Department of Rheumatology, Helsingør and Hillerød Hospital, Hillerød, Denmark, ¹²Department of Rheumatology, Køge Hospital, Køge, East Timor, ¹³Department of Rheumatology, Gentofte University Hospital, Copenhagen, Denmark, ¹⁴Vendsyssel Teaching Hospital/Aalborg University, Hjoerring, Denmark, ¹⁵Department of Rheumatology, Landspitali - The National University Hospital of Iceland, Reykjavik, Iceland, ¹⁶Rheumatology, Department of Rheumatology, Landspitali - The National University Hospital of Iceland, Reykjavik, Iceland, ¹⁷Department of Clinical Medicine, Faculty of Health and Medical Sciences, University of Copenhagen, The Danish Rheumatologic Database (DANBIO), Glostrup Hospital., Copenhagen, Denmark
Background/Purpose: International guidelines recommend that in psoriatic arthritis infliximab should be dosed with 5 mg/kg bodyweight every 8th week. Data on the use of lower…
Abstract Number: 1979 • 2013 ACR/ARHP Annual Meeting
Occupational Balance Questionnaire: From People’s Perspectives To A Patient Reported Outcome
Mona Dür¹, Gunter Steiner², Michaela Stoffer³, Alexandra Kautzky-Willer⁴, Veronika Fialka-Moser⁵, Clemens Dejaco⁶, Birgit Prodinger⁷, Alexa Binder⁸, Josef S. Smolen^9,10 and Tanja A. Stamm¹¹, ¹Internal Medicine III Division of Rheumatology, Medical University of Vienna, Vienna, Austria, ²Internal Medicine III, Division of Rheumatology, Medical University of Vienna, Vienna, Austria, ³Internal Medicine III, division of rheumatology, Medical University of Vienna, Vienna, Austria, ⁴Internal Medicine III, Division of Diabetology, Medical University of Vienna, Vienna, Austria, ⁵Physical Medicine and Rehabilitation, Medical University of Vienna, Vienna, Austria, ⁶Internal Medicine III, Division of Gastroenterology and Hepatology, Medical University of Vienna, Vienna, Austria, ⁷ICF Research Branch, Swiss Paraplegic Group, Nottwil, Switzerland, Notwill, Switzerland, ⁸Occupational therapy, Hospital Goettlicher Heiland, Vienna, Austria, ⁹Medical University of Vienna and Hietzing Hospital, Vienna, Austria, ¹⁰Department of Rheumatology, Medical University of Vienna and Hietzing Hospital, Vienna, Austria, ¹¹Rheumatology, Medical University of Vienna, Vienna, Austria
Background/Purpose: Occupational balance is one of the foundations on which occupational therapy is based. Occupational balance is defined diversely and mainly derived from the perspective…
Abstract Number: 191 • 2013 ACR/ARHP Annual Meeting
Does Specific Joint Involvement In Rheumatoid Arthritis Patients Predict Patient Reported Outcomes? Implications For Clinical Practice
Regan Arendse¹, William G. Bensen², Andrew Chow³, Jude F. Rodrigues⁴, Sanjay Dixit⁵, Dalton E. Sholter⁶, Philip Baer⁷, Milton F. Baker⁸, Denis Choquette⁹, Isabelle Fortin¹⁰, Algis Jovaisas¹¹, Emmanouil Rampakakis¹², John S. Sampalis¹², Francois Nantel¹³, Susan M. Otawa¹⁴, May Shawi¹⁵ and Allen J. Lehman¹⁴, ¹University of Saskatchewan, Saskatoon, SK, Canada, ²Department of Medicine, Division of Rheumatology, Clinical Professor, McMaster University, Hamilton, ON, Canada, ³University of Toronto, McMaster University, Credit Valley Rheumatology, Mississauga, ON, Canada, ⁴Rheumatology, Windsor, ON, Canada, ⁵McMaster University, Hamilton, ON, Canada, ⁶Rheumatology Associates, Edmonton, AB, Canada, ⁷Private Practice, Scarborough, ON, Canada, ⁸University of Victoria, Victoria, BC, Canada, ⁹Rheumatology, Institut de rhumatologie de Montréal (IRM), Montréal, QC, Canada, ¹⁰Centre de rhumatologie de l'est du Québec (CREQ), Rimouski, QC, Canada, ¹¹Division of Rheumatology, University of Ottawa, Ottawa, ON, Canada, ¹²JSS Medical Research, Montreal, QC, Canada, ¹³Janssen Inc., Toronto, ON, Canada, ¹⁴Medical Affairs, Janssen Inc., Toronto, ON, Canada, ¹⁵Medical Affairs, Janssen Canada Inc, Toronto, ON, Canada
Background/Purpose: Assessment of functional (dis)ability in rheumatoid arthritis (RA) is subject to patient judgment when appraising their ability to do daily activities. The aim of…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].